György Miklós Keserű

This study shows that targeting microglial P2Y12 receptor signaling reduces neurodegeneration in Parkinson's disease models using genetic and pharmacological approaches.

The paper identifies cryptic pockets on challenging drug targets using a fast MD-free method and validates them experimentally.

LigandForge generates structure-guided de novo ligands using cheminformatics and visualization tools, refining molecules with reinforcement learning and genetic algorithms.

Deep Docking virtual screening of over five million compounds and structure-activity optimization yielded T2M-010, a submicromolar small-molecule TREM2 agonist that induces SYK phosphorylation and microglial phagocytosis.

This paper identifies two covalent activators of DC-SIGN by screening a lysine-targeted electrophilic fragment library, revealing distinct mechanisms of activation through structural and functional analyses.